Expression, purification, and inhibition of human RET tyrosine kinase

Luca Mologni, Elisa Sala, Barbara Riva, Luca Cesaro, Sara Cazzaniga, Sara Redaelli, Oriano Marin, Nicola Pasquato, Arianna Donella-Deana, Carlo Gambacorti-Passerini

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tyrosine kinases are emerging as frequent targets of primary oncogenic events and therefore represent an optimal focus of therapeutical intervention. Genetic alterations that cause dysregulated activation of the RET tyrosine kinase are responsible for a significant fraction of thyroid carcinomas. In an effort towards therapeutic RET inactivation, we have developed a method for expression and purification of recombinant RET catalytic domain for structural purposes and for use in the screening of potential inhibitors of RET kinase activity. His-tagged RET kinase domain was purified from Sf9 insect cell lysate using a two-step chromatographic protocol and characterised. Purified recombinant RET phosphorylated itself and exogenous substrates at physiological pH. A specific peptide substrate, derived from RET activation loop, was identified and experimentally validated. These reagents were used to develop a rapid ELISA-based kinase assay for screening potential inhibitors. Novel RET inhibitors were identified using this assay.

Original languageEnglish
Pages (from-to)177-185
Number of pages9
JournalProtein Expression and Purification
Volume41
Issue number1
DOIs
Publication statusPublished - May 2005

Fingerprint

Protein-Tyrosine Kinases
Purification
Phosphotransferases
Assays
Screening
Chemical activation
Sf9 Cells
Substrates
Thyroid Neoplasms
Insects
Catalytic Domain
Enzyme-Linked Immunosorbent Assay
Peptides
Therapeutics

Keywords

  • ELISA
  • Immobilised metal affinity chromatography
  • Inhibitor screening
  • PTC
  • RET
  • Thyroid
  • Tyrosine kinase

ASJC Scopus subject areas

  • Biochemistry

Cite this

Mologni, L., Sala, E., Riva, B., Cesaro, L., Cazzaniga, S., Redaelli, S., ... Gambacorti-Passerini, C. (2005). Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expression and Purification, 41(1), 177-185. https://doi.org/10.1016/j.pep.2005.01.002

Expression, purification, and inhibition of human RET tyrosine kinase. / Mologni, Luca; Sala, Elisa; Riva, Barbara; Cesaro, Luca; Cazzaniga, Sara; Redaelli, Sara; Marin, Oriano; Pasquato, Nicola; Donella-Deana, Arianna; Gambacorti-Passerini, Carlo.

In: Protein Expression and Purification, Vol. 41, No. 1, 05.2005, p. 177-185.

Research output: Contribution to journalArticle

Mologni, L, Sala, E, Riva, B, Cesaro, L, Cazzaniga, S, Redaelli, S, Marin, O, Pasquato, N, Donella-Deana, A & Gambacorti-Passerini, C 2005, 'Expression, purification, and inhibition of human RET tyrosine kinase', Protein Expression and Purification, vol. 41, no. 1, pp. 177-185. https://doi.org/10.1016/j.pep.2005.01.002
Mologni, Luca ; Sala, Elisa ; Riva, Barbara ; Cesaro, Luca ; Cazzaniga, Sara ; Redaelli, Sara ; Marin, Oriano ; Pasquato, Nicola ; Donella-Deana, Arianna ; Gambacorti-Passerini, Carlo. / Expression, purification, and inhibition of human RET tyrosine kinase. In: Protein Expression and Purification. 2005 ; Vol. 41, No. 1. pp. 177-185.
@article{dedbd012585143fba75a446344f556f9,
title = "Expression, purification, and inhibition of human RET tyrosine kinase",
abstract = "Tyrosine kinases are emerging as frequent targets of primary oncogenic events and therefore represent an optimal focus of therapeutical intervention. Genetic alterations that cause dysregulated activation of the RET tyrosine kinase are responsible for a significant fraction of thyroid carcinomas. In an effort towards therapeutic RET inactivation, we have developed a method for expression and purification of recombinant RET catalytic domain for structural purposes and for use in the screening of potential inhibitors of RET kinase activity. His-tagged RET kinase domain was purified from Sf9 insect cell lysate using a two-step chromatographic protocol and characterised. Purified recombinant RET phosphorylated itself and exogenous substrates at physiological pH. A specific peptide substrate, derived from RET activation loop, was identified and experimentally validated. These reagents were used to develop a rapid ELISA-based kinase assay for screening potential inhibitors. Novel RET inhibitors were identified using this assay.",
keywords = "ELISA, Immobilised metal affinity chromatography, Inhibitor screening, PTC, RET, Thyroid, Tyrosine kinase",
author = "Luca Mologni and Elisa Sala and Barbara Riva and Luca Cesaro and Sara Cazzaniga and Sara Redaelli and Oriano Marin and Nicola Pasquato and Arianna Donella-Deana and Carlo Gambacorti-Passerini",
year = "2005",
month = "5",
doi = "10.1016/j.pep.2005.01.002",
language = "English",
volume = "41",
pages = "177--185",
journal = "Protein Expression and Purification",
issn = "1046-5928",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Expression, purification, and inhibition of human RET tyrosine kinase

AU - Mologni, Luca

AU - Sala, Elisa

AU - Riva, Barbara

AU - Cesaro, Luca

AU - Cazzaniga, Sara

AU - Redaelli, Sara

AU - Marin, Oriano

AU - Pasquato, Nicola

AU - Donella-Deana, Arianna

AU - Gambacorti-Passerini, Carlo

PY - 2005/5

Y1 - 2005/5

N2 - Tyrosine kinases are emerging as frequent targets of primary oncogenic events and therefore represent an optimal focus of therapeutical intervention. Genetic alterations that cause dysregulated activation of the RET tyrosine kinase are responsible for a significant fraction of thyroid carcinomas. In an effort towards therapeutic RET inactivation, we have developed a method for expression and purification of recombinant RET catalytic domain for structural purposes and for use in the screening of potential inhibitors of RET kinase activity. His-tagged RET kinase domain was purified from Sf9 insect cell lysate using a two-step chromatographic protocol and characterised. Purified recombinant RET phosphorylated itself and exogenous substrates at physiological pH. A specific peptide substrate, derived from RET activation loop, was identified and experimentally validated. These reagents were used to develop a rapid ELISA-based kinase assay for screening potential inhibitors. Novel RET inhibitors were identified using this assay.

AB - Tyrosine kinases are emerging as frequent targets of primary oncogenic events and therefore represent an optimal focus of therapeutical intervention. Genetic alterations that cause dysregulated activation of the RET tyrosine kinase are responsible for a significant fraction of thyroid carcinomas. In an effort towards therapeutic RET inactivation, we have developed a method for expression and purification of recombinant RET catalytic domain for structural purposes and for use in the screening of potential inhibitors of RET kinase activity. His-tagged RET kinase domain was purified from Sf9 insect cell lysate using a two-step chromatographic protocol and characterised. Purified recombinant RET phosphorylated itself and exogenous substrates at physiological pH. A specific peptide substrate, derived from RET activation loop, was identified and experimentally validated. These reagents were used to develop a rapid ELISA-based kinase assay for screening potential inhibitors. Novel RET inhibitors were identified using this assay.

KW - ELISA

KW - Immobilised metal affinity chromatography

KW - Inhibitor screening

KW - PTC

KW - RET

KW - Thyroid

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=20144364772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144364772&partnerID=8YFLogxK

U2 - 10.1016/j.pep.2005.01.002

DO - 10.1016/j.pep.2005.01.002

M3 - Article

C2 - 15802236

AN - SCOPUS:20144364772

VL - 41

SP - 177

EP - 185

JO - Protein Expression and Purification

JF - Protein Expression and Purification

SN - 1046-5928

IS - 1

ER -